Manuel Quaresma Selected Research

nintedanib

1/2022	Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
1/2022	Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
4/2021	Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.
11/2020	Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis.
1/2020	Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
1/2020	Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.
1/2020	Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON.
1/2020	Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
12/2019	Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE).
10/2019	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manuel Quaresma Research Topics

Disease

20	Idiopathic Pulmonary Fibrosis 01/2022 - 09/2015
5	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 10/2019
5	Disease Progression 01/2020 - 01/2019
4	Diarrhea 01/2022 - 09/2015
3	Fibrosis (Cirrhosis) 01/2020 - 03/2019
2	Lung Diseases (Lung Disease) 01/2022 - 10/2019
2	Hemorrhage 01/2019 - 01/2019
1	Systemic Scleroderma (Systemic Sclerosis) 01/2022
1	Autoimmune Diseases (Autoimmune Disease) 01/2022
1	Weight Loss (Weight Reduction) 11/2020
1	Emphysema 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2020
1	Extrinsic Allergic Alveolitis (Hypersensitivity Pneumonitis) 01/2020
1	Idiopathic Interstitial Pneumonias 01/2020
1	Nausea 09/2019
1	Lung Injury 03/2019
1	Myocardial Infarction 01/2019
1	Dyspnea (Shortness of Breath) 11/2018

Drug/Important Bio-Agent (IBA)

21	nintedanibIBA 01/2022 - 09/2015
4	pirfenidoneIBA 01/2020 - 01/2018
3	Carbon MonoxideIBA 01/2022 - 10/2019
2	Sildenafil Citrate (Viagra)FDA Link 12/2019 - 11/2018
2	Tyrosine (L-Tyrosine)FDA Link 10/2019 - 03/2019
2	Phosphotransferases (Kinase)IBA 10/2019 - 03/2019
1	AutoantibodiesIBA 01/2022
1	Brain Natriuretic Peptide (Natrecor)FDA Link 12/2019
1	EnzymesIBA 01/2019
1	Tyrosine Kinase InhibitorsIBA 01/2019

Therapy/Procedure

2	Therapeutics 11/2020 - 03/2019
1	Precision Medicine 01/2020
1	Lung Transplantation 01/2020